Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Immutep Announces Results of Annual General Meeting (ASX:IMM)

The results of Immutep Limited (ASX:IMM) Annual General Meeting held earlier today are set out in the attached document. All resolutions were passed on a show of hands. For further information...read more

Immutep, Chairman's Address 2018 Annual General Meeting (ASX:IMM)

Dr Russell Howard On behalf of the Board, I welcome you to Immutep’s Annual General Meeting for 2018. I am pleased to address you for the first time as Chairman of your company, after taki...read more

Immutep, CEO Presentation Annual General Meeting November 2018 (ASX:IMM)

The global leader in developing LAG-3 therapeutics 2018 Summary Strong operational and financial progress Continued focus on LAG-3 immunotherapy Progressed the development of four LAG-3...read more

Imugene Advances to Phase 2 in Gastric Cancer Immuno-oncology Trial (ASX:IMU)

Phase 1b study objectives met; all dose levels showed increased antibody levels in all patients Phase 2 study on track to start early 2019 Dose level confirmed for Phase 2 with no safety issu...read more

Noxopharm to Present Clinical Data at COSA 2018 Annual Meeting (ASX:NOX)

Clinical Oncology Society of Australia Provides updates on CEP-1 and DARRT-1 clinical studies Confirms tolerability of Veyonda Evidence of durable halt of tumour progression in both studi...read more

Immutep Presents Positive New Data from Ongoing TACTI-mel Study at Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting (ASX:IMM)

SYDNEY, AUSTRALIA – November 12, 2018 – Immutep Limited (ASX:IMM; NASDAQ:IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy t...read more

Imugene Advises $1.85 Million R&D Tax Incentive Received (ASX:IMU)

SYDNEY, Australia, 9 November 2018: Imugene Limited (ASX:IMU), an immuno- oncology company is pleased to advise that it has received a research and development (R&D) tax refund of $1.85 million as...read more

Noxopharm Releases Latest Corporate Presentation November 2018 (ASX:NOX)

Investment Highlights Leader in the development of isoflavonoid-based therapeutics, an emerging field of drug development - Novel family of G-protein inhibitors blocking key signaling pathways ...read more

Immutep Provides Operational Update (ASX:IMM)

Highlights Site selection process advancing for planned TACTI-002 Phase II trial which will include recruitment of up to 110 patients AIPAC Phase IIb recruitment reaches 155 patients or more t...read more

Immutep, Investor Presentation (ASX:IMM)

The global leader in developing LAG-3 therapeutics Australia Biotech Invest & Partnering 30th October 2018 Company Snapshot Globally active biotechnology company with operations in Austr...read more

Noxopharm Releases September Quarter 2018 Appendix 4C (ASX:NOX)

Sydney, 26 October 2018: Noxopharm (ASX:NOX) today releases its Appendix 4C for the quarter ended 30 September 2018, as well as providing guidance on the next 12-18 months. This report is presented...read more

Immutep, Appendix 4C (ASX:IMM)

Quarterly report for entities subject to Listing Rule 4.7B Quarter ended: 30th September 2018 To view Report please download PDF attached:

Immutep Announces Data Presentations at Upcoming Industry Conferences (ASX:IMM)

SYDNEY, AUSTRALIA – October 24, 2018 – Immutep Limited (ASX:IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy t...read more

Noxopharm Announces Key Executive Appointment (ASX:NOX)

Chief Medical Officer appointed Early clinical trial data leads to expanded clinical trial program Company prepares for pre-commercial phase Sydney, 22 October 2018: Noxopharm (ASX:NOX) is...read more